Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Inmed Pharmaceuticals IN (IN.TO)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 41,348
  • Shares Outstanding, K 172,284
  • Annual Sales, $ 0 K
  • Annual Income, $ -13,255 K
  • 60-Month Beta 6.22
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 2.27
  • Price/Earnings ttm N/A
  • Earnings Per Share ttm -0.08
  • Most Recent Earnings -0.03 on 06/30/19
  • Next Earnings Date 11/08/19
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.24 unch
on 11/20/19
0.32 -25.00%
on 11/08/19
-0.03 (-11.11%)
since 10/18/19
3-Month
0.22 +9.09%
on 08/27/19
0.45 -46.67%
on 09/04/19
-0.02 (-7.69%)
since 08/20/19
52-Week
0.22 +9.09%
on 08/27/19
0.80 -70.00%
on 02/05/19
-0.28 (-53.85%)
since 11/20/18

Most Recent Stories

More News
Edison issues update on InMed Pharmaceuticals

LONDON, UK / ACCESSWIRE / November 18, 2019 / InMed Pharmaceuticals (TSX:IN) recently announced that it filed a Clinical Trial Application in the Netherlands for INM-755, which is being developed for epidermolysis...

IMLFF : 0.1800 (-4.05%)
IN.TO : 0.24 (unch)
InMed Pharmaceuticals to Present at the Cowen Conference

VANCOUVER , Nov. 11, 2019 /PRNewswire/ - InMed Pharmaceuticals Inc. ("InMed" or "the Company") (TSX:IN; OTCQX:IMLFF), a biopharmaceutical company developing a proprietary biosynthesis manufacturing...

IMLFF : 0.1800 (-4.05%)
IN.TO : 0.24 (unch)
InMed Pharmaceuticals Reports First Quarter Fiscal 2020 Financial Results and Provides R&D and Business Update

VANCOUVER , Nov. 8, 2019 /PRNewswire/ - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (TSX: IN; OTCQX: IMLFF), a biopharmaceutical company developing a proprietary biosynthesis manufacturing...

IMLFF : 0.1800 (-4.05%)
IN.TO : 0.24 (unch)
InMed Submits Clinical Trial Application to Evaluate INM-755 in Phase 1 Trial

VANCOUVER , Nov. 5, 2019 /PRNewswire/ -  InMed Pharmaceuticals Inc. ("InMed" or the "Company") (TSX: IN; OTCQX: IMLFF), today announced the filing of a Clinical Trial Application ("CTA") in...

IMLFF : 0.1800 (-4.05%)
IN.TO : 0.24 (unch)
InMed Pharmaceuticals to Report First Quarter Fiscal 2020 Financial Results and Business Update on November 8, 2019

VANCOUVER , Nov. 4, 2019 /PRNewswire/ - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (TSX:IN; OTCQX:IMLFF), a biopharmaceutical company developing a proprietary biosynthesis manufacturing...

IMLFF : 0.1800 (-4.05%)
IN.TO : 0.24 (unch)
InMed Pharmaceuticals to Present at the BIO Investor Forum

VANCOUVER , Oct. 18, 2019 /PRNewswire/ - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (TSX:IN; OTCQX:IMLFF), a biopharmaceutical company developing a proprietary biosynthesis manufacturing...

IMLFF : 0.1800 (-4.05%)
IN.TO : 0.24 (unch)
InMed Pharmaceuticals to Present at the Regulatory Affairs Professionals Society's annual conference

VANCOUVER , Sept. 23, 2019 /PRNewswire/ - InMed Pharmaceuticals Inc. ("InMed" or "the Company") (TSX:IN; OTCQX:IMLFF), a biopharmaceutical company developing a proprietary biosynthesis manufacturing...

IMLFF : 0.1800 (-4.05%)
IN.TO : 0.24 (unch)
InMed Pharmaceuticals Reports Fourth Quarter and Full Year Fiscal 2019 Financial Results and Provides R&D and Business Update

TSX:IN OTCQX:IMLFF

IMLFF : 0.1800 (-4.05%)
IN.TO : 0.24 (unch)
InMed Pharmaceuticals to Report Fourth Quarter, and Full Year Fiscal 2019 Financial Results and Business Update on September 19, 2019

TSX:IN OTCQX:IMLFF

IMLFF : 0.1800 (-4.05%)
IN.TO : 0.24 (unch)
InMed Pharmaceuticals to Present at the H.C. Wainwright 21st Annual Global Investment Conference

Martin Bott steps down from the Board of Directors

IMLFF : 0.1800 (-4.05%)
IN.TO : 0.24 (unch)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 96% Sell with a Strengthening short term outlook on maintaining the current direction.

Longer term, the trend strength is Good. Long term indicators fully support a continuation of the trend.

See More Share

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar